Compass Therapeutics (NASDAQ:CMPX – Get Free Report) had its target price lowered by equities research analysts at Wedbush from $1.00 to $0.90 in a research note issued on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Wedbush‘s target price indicates a potential upside of 8.41% from the stock’s previous close.
A number of other research analysts have also recently issued reports on CMPX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Thursday, October 15th. Citizens Jmp dropped their target price on Compass Therapeutics to $4.00 and set a “market outperform” rating on the stock in a report on Wednesday, September 23rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Compass Therapeutics in a research note on Wednesday, September 23rd. Piper Sandler raised their price target on Compass Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, Wall Street Zen lowered Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $9.99.
Get Our Latest Research Report on CMPX
Compass Therapeutics Stock Performance
Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). As a group, sell-side analysts forecast that Compass Therapeutics will post -0.48 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Compass Therapeutics
A number of institutional investors have recently made changes to their positions in the company. Parallel Advisors LLC bought a new stake in shares of Compass Therapeutics during the first quarter valued at approximately $28,000. PNC Financial Services Group Inc. lifted its position in Compass Therapeutics by 2,572.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 11,038 shares of the company’s stock valued at $58,000 after acquiring an additional 10,625 shares in the last quarter. HB Wealth Management LLC bought a new position in Compass Therapeutics in the 2nd quarter valued at approximately $29,000. State of Wyoming purchased a new stake in Compass Therapeutics during the 2nd quarter valued at $31,000. Finally, Pictet Asset Management Holding SA purchased a new stake in Compass Therapeutics during the 1st quarter valued at $76,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.
Compass Therapeutics Company Profile
Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research centers on immuno-oncology and other approaches intended to target biological pathways involved in tumor growth and the body’s immune response. One of its investigational programs is CTX-009, a bispecific antibody designed to target DLL4 and VEGF-A, proteins associated with tumor blood-vessel development. Compass is also advancing other antibody programs for potential use against solid tumors.
Further Reading
- Five stocks we like better than Compass Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
